Evidence map›Paper›PMID 18241233›Full record

ArticleClinical and experimental immunology2008

Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.

R Pérez de Diego, E López-Granados, J Rivera, A Ferreira, G Fontán, J Bravo, M C García Rodríguez, S Bolland

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

R Pérez de DiegoSignal Transduction Group, Spanish National Cancer Research Centre (CNIO), Madrid, and Immunology Unit, Unviersity Hospital La Paz, Madrid, Spain. rperez@cnio.es
E López-Granados
J Rivera
A Ferreira
G Fontán
J Bravo
M C García Rodríguez
S Bolland
Hospital Universitario La Paz · ESSpanish National Cancer Research Centre · ESNational Institute of Allergy and Infectious Diseases · US

Funding

Regulation Of The Immune Response By The Inositol Phosphatase SHIPZ01AI000911 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI BOLLAND, SILVIA · 2002 to 2008
$1.3M
Regulation Of The Immune Response By The Inositol Phosphatase SHIPZIAAI000911 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BOLLAND, SILVIA · 2009 to 2010
$581k
Intramural NIH HHS
6 · The paper itself

Abstract

X-linked agammaglobulinaemia (XLA) is characterized by absence of mature B cells because of mutations in the Bruton's tyrosine kinase (Btk) gene. Btk-deficient early B cell precursors experience a block in their differentiation potentially reversible by the addition of an intact Btk gene. Btk expression was measured in 69 XLA patients with 47 different mutations and normal expression was detected in seven. We characterized these Btk mutant forms functionally by transfection into a lymphoma cell line that lacks endogenous Btk expression (Btk-/- DT40 cells) and analysed the calcium flux in response to B cell receptor stimulation. To test whether co-expression of a mutated form could compromise the function of the intact Btk transfection, studies in wild-type (WT) DT40 cells were also performed. Study reveals that none of the seven Btk mutants analysed was able to revert the absence of calcium mobilization upon IgM engagement in Btk-/- DT40 cells, as does intact Btk. In addition, calcium mobilization by anti-IgM stimulation in DT40 Btk+/+ cells was unaffected by co-expression with Btk mutants. These results suggest that gene addition would be feasible not only for patients with XLA and mutations that prevent Btk expression, but for those with expression of a mutant Btk.

Indexed as

MutationAgammaglobulinaemia Tyrosine KinaseAgammaglobulinemiaAnimalsCalciumChickensChildChild, PreschoolGenetic Diseases, X-LinkedHumansImmunoglobulin MInfantMaleMutagenesis, Site-DirectedMutation, MissenseProtein-Tyrosine KinasesAgammaglobulinaemia Tyrosine KinaseBTK protein, humanCalciumImmunoglobulin MProtein-Tyrosine Kinases

Identifiers

PMID18241233
PMCPMC2384054
OpenAlexW1569214216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.